Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Today, the biotech-vaccine company Intercell AG announced its financial results for Q1 and presented an update on the Company's development programs.

11 May 2010

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

IQuum, Inc. today announced it has been granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Liat™ Influenza A/2009 H1N1 Assay. The assay detects and differentiates 2009 H1N1 influenza viral RNA starting from collected nasopharyngeal swab samples in less than 30 minutes.

10 May 2010

Challenges and limitations faced in avian influenza

Over the past decade, substantial resources have been spent on tackling avian influenza and building a global capacity for a pandemic response. The catastrophic costs of the 1918 influenza pandemic are well documented, and the swine flu pandemic of 2009-10 has raised the alarm yet again.

7 May 2010

Methane in breath linked to obesity

New Cedars-Sinai research shows obese patients who test positive for methane on their breath have a significantly higher body mass index (BMI) than their peers.

7 May 2010

HealthMap's H1N1 survey identifies disparities in international public health systems

As H1N1 began to emerge in April 2009, HealthMap - an automated online disease tracking and mapping tool created by researchers in the Informatics Program at Children's Hospital Boston - was already collecting information about the virus and plotting that information on a map of the globe, creating a freely available, real-time, digestible display of the outbreak.

7 May 2010

WHO publishes comprehensive report on H1N1

"A year after the H1N1 [swine] flu first appeared, the World Health Organization has issued perhaps the most comprehensive report on the pandemic's activity to date," HealthDay News/Bloomberg BusinessWeek reports (Gardner, 5/5).

7 May 2010

Gentiva Health Services first-quarter total net revenues up 7.5% to $297.1 million

Gentiva Health Services, Inc., a leading provider of home health and hospice services, today reported first quarter 2010 results.

6 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Experts unveil roadmap to improve health and health delivery in the U.S.

A Commission of national health care experts convened by the Center for the Study of the Presidency and Congress has unveiled a roadmap and integrated approach that will put "health" back into our nation's health care system as well as address key opportunities following passage of health care reform legislation.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Vical Incorporated today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Author of new study calls for responsible media coverage of public health emergencies

A study of emergency department activity before and during the H1N1 influenza pandemic highlights the role public fear can play in unnecessarily straining medical facilities and will aid in ongoing preparations for public health emergencies, according to the authors.

4 May 2010

H1N1 positivity highest among children

More than 99 percent of specimens tested for influenza were positive for H1N1 over approximately the past 11 months, according to a report released today from Quest Diagnostics Incorporated ( DGX). The Quest Diagnostics Health Trends™ Report suggests that H1N1 "crowded out" other influenza viruses to be the dominant flu virus of the 2009-2010 flu season.

4 May 2010

Older children hospitalized with pandemic H1N1 influenza in 2009: Study

Children hospitalized with pandemic H1N1 influenza in 2009 were older and more likely to have underlying medical conditions than children hospitalized with seasonal influenza during prior flu seasons, according to a study to be presented Tuesday, May 4 at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.

4 May 2010

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.

3 May 2010

Researcher finds evidence of how human behavior can influence emergence of infectious disease

After studying the interactions of human and animal populations in Africa, Kathleen Alexander, associate professor of wildlife science in Virginia Tech's College of Natural Resources, found powerful evidence of how human behavior can influence the emergence of infectious disease in humans and animals.

3 May 2010

Seasonal flu vaccine ups the risk of getting H1N1 flu

Initial reports linking seasonal flu vaccine and getting swine flu or H1N1 flu emerged September 2009 in Canada. In spring 2009 many people who acquired pandemic H1N1 flu had been initially vaccinated with seasonal flu vaccine. This triggered four additional studies in Canada to explore the link further. The studies included 2,700 patients with or without H1N1. The first of the studies showed a surprising 68 percent rise of risk of development of H1N1 flu in those vaccinated with seasonal flu shot. The other 3 studies showed increase of risk of H1N1 flu by 1.4 to 1.5 times with the original flu shot.

2 May 2010

Pandemic News and Research

Further Reading

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

Challenges and limitations faced in avian influenza

Methane in breath linked to obesity

HealthMap's H1N1 survey identifies disparities in international public health systems

WHO publishes comprehensive report on H1N1

Gentiva Health Services first-quarter total net revenues up 7.5% to $297.1 million

Vical reports net loss of $8.5 million for first-quarter 2010

Experts unveil roadmap to improve health and health delivery in the U.S.

Update on CEL-SCI's Phase III clinical trial of Multikine

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

MicroStockProfit.com releases investment report on Vical

Author of new study calls for responsible media coverage of public health emergencies

H1N1 positivity highest among children

Older children hospitalized with pandemic H1N1 influenza in 2009: Study

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

Researcher finds evidence of how human behavior can influence emergence of infectious disease

Seasonal flu vaccine ups the risk of getting H1N1 flu

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News